Sling Therapeutics Announces $123 Million Series C Financing to Advance Phase 3 Development of its Oral Small Molecule IGF-1R Inhibitor for Thyroid Eye Disease

Sling Therapeutics closed a $123 million Series C financing led by Forbion, with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management. The capital will support continued clinical development of its late-stage oral small-molecule therapy for thyroid eye disease, strengthening the company’s funding runway and development prospects.

Analysis

The relevant public read-through is negative for Amgen’s TEPEZZA franchise and raises the competitive bar for Viridian (VRDN): a credible oral entrant would pressure both infusion-site economics and the premium pricing supported by IV administration. The most material value shift is not near-term revenue displacement, but a lower terminal-value assumption for TED exclusivity if an oral option can demonstrate comparable proptosis efficacy with cleaner hearing, hyperglycemia, and GI tolerability. For AMGN, the market is unlikely to re-rate on this financing alone, but TEPEZZA’s multiple contribution becomes more vulnerable as pivotal trial design, enrollment pace, and durability data emerge over the next 12-24 months.

This is a financing event rather than independent clinical validation, and the absence of disclosed valuation, cash runway, and trial milestones limits its immediate trading utility. The contrarian view is that oral convenience may not translate into rapid share capture: TED specialists have established infusion workflows, and payers may demand robust active-disease efficacy plus durability and safety evidence before switching from a proven biologic. A successful oral program could also expand the treated population by lowering treatment friction, partially offsetting price/share pressure on incumbent therapies rather than creating a zero-sum market.

Near term, monitor clinical-trial registry updates, enrollment completion, and any disclosed endpoint assumptions rather than extrapolating from the capital raise. A positive efficacy signal would likely hurt AMGN sentiment before affecting estimates, while VRDN could initially benefit from category validation but later face valuation compression if the oral profile appears commercially superior. The thesis is falsified if the oral candidate shows materially weaker proptosis response, poor durability, or safety liabilities that preserve IV therapies’ risk-benefit advantage.

Key Decisions for Investors

• No immediate directional position solely on this event; create a 12-18 month competitive-risk watch on AMGN, with emphasis on TEPEZZA net sales guidance and any change in management’s TED peak-sales commentary.
• Use VRDN as the liquid TED-development proxy rather than assuming a positive read-through: consider long VRDN only after comparing pivotal endpoint, dosing burden, and safety disclosures against the oral program. Category validation is constructive, but an apparently superior oral profile would be a medium-term competitive negative.
• For existing AMGN holders, consider modest downside hedges around upcoming TED competitor data windows rather than reducing core exposure now; the key risk is multiple compression on franchise durability, not a 2026 earnings miss. Remove the hedge if competitor data fail to show clinically meaningful proptosis efficacy and acceptable tolerability.
• Watch for payer or physician evidence that an oral treatment can shift patients earlier in the treatment pathway. That would increase TED market size and could support both AMGN and VRDN initially, while making long-term pricing pressure more likely.